Literature DB >> 2618078

Biological fate of sirdalud in animals and man.

P Koch1, D R Hirst, B R von Wartburg.   

Abstract

1. Biotransformation and excretion of the muscle relaxant drug, sirdalud, were studied after oral doses of 14C- and 3H-sirdalud in rats, dogs, rabbits, mice and humans. Sirdalud was well absorbed and almost completely metabolized in the five species. 2. Excretion of metabolites was rapid and complete within a few days; the urine/faeces excretion ratio of the 14C label was about 70/30 in all species. Major metabolic pathways of sirdalud were oxidative degradation of the imidazoline ring and oxidation of the aromatic system. 3. A novel oxidative biotransformation pathway of the benzothiadiazole ring system of sirdalud gave a sulphone analogue of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2618078     DOI: 10.3109/00498258909043177

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

2.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.

Authors:  Janne T Backman; Marjo J Karjalainen; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 3.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

5.  Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.

Authors:  Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

6.  5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothia-diazol-4-amine (tizanidine).

Authors:  Peter John; Islam Ullah Khan; Mehmet Akkurt; Muhammad Shahid Ramzan; Shahzad Sharif
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.